APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

GnRH Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GnRH Receptor Antagonists Market Outlook and Growth Opportunities 2026

Report ID 17399603042 January 2026193 pages

Choose your research edition.

Industry ResearchGnRH Receptor Antagonists Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal GnRH Receptor Antagonists Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal GnRH Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GnRH Receptor Antagonists Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal GnRH Receptor Antagonists Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global GnRH Receptor Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GnRH Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GnRH Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GnRH Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GnRH Receptor Antagonists market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GnRH Receptor Antagonists market include Ferring Pharmaceuticals, Kissei, Myovant Sciences, Veru Inc, AstraZeneca, AbbVie, Astellas, Jiangsu Hengrui Medicine Co and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GnRH Receptor Antagonists market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GnRH Receptor Antagonists and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GnRH Receptor Antagonists sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GnRH Receptor Antagonists market size, projected growth trends, production technologies, key applications, and end-use industries.

GnRH Receptor Antagonists Segment by Company

Ferring Pharmaceuticals

Kissei

Myovant Sciences

Veru Inc

AstraZeneca

AbbVie

Astellas

Jiangsu Hengrui Medicine Co

Takeda

GnRH Receptor Antagonists Segment by Type

Peptides

Small Molecules

GnRH Receptor Antagonists Segment by Application

Endometriosis

Uterine Fibroids

Prostate Cancer

Female Infertility

Others

GnRH Receptor Antagonists Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global GnRH Receptor Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions GnRH Receptor Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GnRH Receptor Antagonists significant trends, drivers, influence factors in global and regions.

6. To analyze GnRH Receptor Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GnRH Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GnRH Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GnRH Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GnRH Receptor Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GnRH Receptor Antagonists industry.

Chapter 3: Detailed analysis of GnRH Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of GnRH Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of GnRH Receptor Antagonists in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GnRH Receptor Antagonists Industry Trends Table 2. GnRH Receptor Antagonists Industry Drivers Table 3. GnRH Receptor Antagonists Industry Opportunities and Challenges Table 4. GnRH Receptor Antagonists Industry Restraints Table 5. Global GnRH Receptor Antagonists Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GnRH Receptor Antagonists Revenue Share by Company (2021-2026) Table 7. Global GnRH Receptor Antagonists Sales Volume by Company (W Units) & (2021-2026) Table 8. Global GnRH Receptor Antagonists Sales Volume Share by Company (2021-2026) Table 9. Global GnRH Receptor Antagonists Average Price (US$/Unit) of Company (2021-2026) Table 10. Global GnRH Receptor Antagonists Company Ranking, (2024-2026) & (USD Million) Table 11. Global GnRH Receptor Antagonists Key Company Manufacturing Base & Headquarters Table 12. Global GnRH Receptor Antagonists Company, Product Type & Application Table 13. Global GnRH Receptor Antagonists Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global GnRH Receptor Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Peptides Table 18. Significant Companies of Small Molecules Table 19. Global GnRH Receptor Antagonists Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 20. Global GnRH Receptor Antagonists Sales Volume by Type (2021-2026) & (W Units) Table 21. Global GnRH Receptor Antagonists Sales Volume by Type (2027-2032) & (W Units) Table 22. Global GnRH Receptor Antagonists Sales Volume Share by Type (2021-2026) Table 23. Global GnRH Receptor Antagonists Sales Volume Share by Type (2027-2032) Table 24. Global GnRH Receptor Antagonists Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global GnRH Receptor Antagonists Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global GnRH Receptor Antagonists Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global GnRH Receptor Antagonists Sales Value Share by Type (2021-2026) Table 28. Global GnRH Receptor Antagonists Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Endometriosis Table 30. Significant Companies of Uterine Fibroids Table 31. Significant Companies of Prostate Cancer Table 32. Significant Companies of Female Infertility Table 33. Significant Companies of Others Table 34. Global GnRH Receptor Antagonists Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 35. Global GnRH Receptor Antagonists Sales Volume by Application (2021-2026) & (W Units) Table 36. Global GnRH Receptor Antagonists Sales Volume by Application (2027-2032) & (W Units) Table 37. Global GnRH Receptor Antagonists Sales Volume Share by Application (2021-2026) Table 38. Global GnRH Receptor Antagonists Sales Volume Share by Application (2027-2032) Table 39. Global GnRH Receptor Antagonists Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 40. Global GnRH Receptor Antagonists Sales Value by Application (2021-2026) & (US$ Million) Table 41. Global GnRH Receptor Antagonists Sales Value by Application (2027-2032) & (US$ Million) Table 42. Global GnRH Receptor Antagonists Sales Value Share by Application (2021-2026) Table 43. Global GnRH Receptor Antagonists Sales Value Share by Application (2027-2032) Table 44. Global GnRH Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 45. Global GnRH Receptor Antagonists Sales by Region (2021-2026) & (W Units) Table 46. Global GnRH Receptor Antagonists Sales Market Share by Region (2021-2026) Table 47. Global GnRH Receptor Antagonists Sales by Region (2027-2032) & (W Units) Table 48. Global GnRH Receptor Antagonists Sales Market Share by Region (2027-2032) Table 49. Global GnRH Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global GnRH Receptor Antagonists Sales Value by Region (2021-2026) & (US$ Million) Table 51. Global GnRH Receptor Antagonists Sales Value Share by Region (2021-2026) Table 52. Global GnRH Receptor Antagonists Sales Value by Region (2027-2032) & (US$ Million) Table 53. Global GnRH Receptor Antagonists Sales Value Share by Region (2027-2032) Table 54. Global GnRH Receptor Antagonists Market Average Price (US$/Unit) by Region (2021-2026) Table 55. Global GnRH Receptor Antagonists Market Average Price (US$/Unit) by Region (2027-2032) Table 56. Global GnRH Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Global GnRH Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global GnRH Receptor Antagonists Sales by Country (2021-2026) & (W Units) Table 59. Global GnRH Receptor Antagonists Sales Market Share by Country (2021-2026) Table 60. Global GnRH Receptor Antagonists Sales by Country (2027-2032) & (W Units) Table 61. Global GnRH Receptor Antagonists Sales Market Share by Country (2027-2032) Table 62. Global GnRH Receptor Antagonists Sales Value by Country (2021-2026) & (US$ Million) Table 63. Global GnRH Receptor Antagonists Sales Value Market Share by Country (2021-2026) Table 64. Global GnRH Receptor Antagonists Sales Value by Country (2027-2032) & (US$ Million) Table 65. Global GnRH Receptor Antagonists Sales Value Market Share by Country (2027-2032) Table 66. Ferring Pharmaceuticals Company Information Table 67. Ferring Pharmaceuticals Business Overview Table 68. Ferring Pharmaceuticals GnRH Receptor Antagonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Ferring Pharmaceuticals GnRH Receptor Antagonists Product Portfolio Table 70. Ferring Pharmaceuticals Recent Development Table 71. Kissei Company Information Table 72. Kissei Business Overview Table 73. Kissei GnRH Receptor Antagonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Kissei GnRH Receptor Antagonists Product Portfolio Table 75. Kissei Recent Development Table 76. Myovant Sciences Company Information Table 77. Myovant Sciences Business Overview Table 78. Myovant Sciences GnRH Receptor Antagonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Myovant Sciences GnRH Receptor Antagonists Product Portfolio Table 80. Myovant Sciences Recent Development Table 81. Veru Inc Company Information Table 82. Veru Inc Business Overview Table 83. Veru Inc GnRH Receptor Antagonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Veru Inc GnRH Receptor Antagonists Product Portfolio Table 85. Veru Inc Recent Development Table 86. AstraZeneca Company Information Table 87. AstraZeneca Business Overview Table 88. AstraZeneca GnRH Receptor Antagonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. AstraZeneca GnRH Receptor Antagonists Product Portfolio Table 90. AstraZeneca Recent Development Table 91. AbbVie Company Information Table 92. AbbVie Business Overview Table 93. AbbVie GnRH Receptor Antagonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. AbbVie GnRH Receptor Antagonists Product Portfolio Table 95. AbbVie Recent Development Table 96. Astellas Company Information Table 97. Astellas Business Overview Table 98. Astellas GnRH Receptor Antagonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Astellas GnRH Receptor Antagonists Product Portfolio Table 100. Astellas Recent Development Table 101. Jiangsu Hengrui Medicine Co Company Information Table 102. Jiangsu Hengrui Medicine Co Business Overview Table 103. Jiangsu Hengrui Medicine Co GnRH Receptor Antagonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Jiangsu Hengrui Medicine Co GnRH Receptor Antagonists Product Portfolio Table 105. Jiangsu Hengrui Medicine Co Recent Development Table 106. Takeda Company Information Table 107. Takeda Business Overview Table 108. Takeda GnRH Receptor Antagonists Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Takeda GnRH Receptor Antagonists Product Portfolio Table 110. Takeda Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. GnRH Receptor Antagonists Distributors List Table 114. GnRH Receptor Antagonists Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. GnRH Receptor Antagonists Product Image Figure 2. Global GnRH Receptor Antagonists Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GnRH Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 4. Global GnRH Receptor Antagonists Sales (2021-2032) & (W Units) Figure 5. Global GnRH Receptor Antagonists Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global GnRH Receptor Antagonists Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Peptides Image Figure 10. Small Molecules Image Figure 11. Global GnRH Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 12. Global GnRH Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global GnRH Receptor Antagonists Sales Volume Share by Type (2021-2032) Figure 14. Global GnRH Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global GnRH Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global GnRH Receptor Antagonists Sales Value Share by Type (2021-2032) Figure 17. Endometriosis Image Figure 18. Uterine Fibroids Image Figure 19. Prostate Cancer Image Figure 20. Female Infertility Image Figure 21. Others Image Figure 22. Global GnRH Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 23. Global GnRH Receptor Antagonists Sales Volume Share 2021 VS 2025 VS 2032 Figure 24. Global GnRH Receptor Antagonists Sales Volume Share by Application (2021-2032) Figure 25. Global GnRH Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global GnRH Receptor Antagonists Sales Value Share 2021 VS 2025 VS 2032 Figure 27. Global GnRH Receptor Antagonists Sales Value Share by Application (2021-2032) Figure 28. Global GnRH Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 29. Global GnRH Receptor Antagonists Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 30. Global GnRH Receptor Antagonists Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 31. Global GnRH Receptor Antagonists Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 32. North America GnRH Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 33. North America GnRH Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Europe GnRH Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 35. Europe GnRH Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Asia-Pacific GnRH Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 37. Asia-Pacific GnRH Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 38. South America GnRH Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 39. South America GnRH Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 40. Middle East & Africa GnRH Receptor Antagonists Sales Value (2021-2032) & (US$ Million) Figure 41. Middle East & Africa GnRH Receptor Antagonists Sales Value Share by Country (%), 2025 VS 2032 Figure 42. USA GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. USA GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. USA GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Canada GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Canada GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Canada GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Mexico GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Mexico GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Mexico GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Germany GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Germany GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Germany GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. France GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. France GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. France GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. U.K. GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. U.K. GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. U.K. GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Italy GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Italy GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Italy GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Spain GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Spain GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Spain GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Russia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Russia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Russia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Netherlands GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Netherlands GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Netherlands GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Nordic Countries GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Nordic Countries GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Nordic Countries GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. China GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. China GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. China GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Japan GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Japan GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Japan GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. South Korea GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. South Korea GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. South Korea GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. India GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. India GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. India GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Australia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Australia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Australia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Southeast Asia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Southeast Asia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Southeast Asia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Brazil GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Brazil GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Brazil GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Argentina GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Argentina GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Argentina GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Chile GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Chile GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Chile GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Colombia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Colombia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Colombia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Peru GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Peru GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Peru GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Saudi Arabia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Saudi Arabia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Saudi Arabia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Israel GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Israel Arabia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Israel Arabia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. UAE GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. UAE GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. UAE GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Turkey GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Turkey GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Turkey GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Iran GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Iran GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Iran GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Egypt GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Egypt GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Egypt GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. GnRH Receptor Antagonists Value Chain Figure 127. Manufacturing Cost Structure Figure 128. GnRH Receptor Antagonists Sales Mode & Process Figure 129. Direct Comparison with Distribution Share Figure 130. Distributors Profiles Figure 131. Years Considered Figure 132. Research Process Figure 133. Key Executives Interviewed

Scope & coverage.

Types
  • Peptides
  • Small Molecules
Applications
  • Endometriosis
  • Uterine Fibroids
  • Prostate Cancer
  • Female Infertility
  • Others
Companies covered
  • Ferring Pharmaceuticals
  • Kissei
  • Myovant Sciences
  • Veru Inc
  • AstraZeneca
  • AbbVie
  • Astellas
  • Jiangsu Hengrui Medicine Co
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GnRH Receptor Antagonists Sales Value (2021-2032)
  4. 1.2.2 Global GnRH Receptor Antagonists Sales Volume (2021-2032)
  5. 1.2.3 Global GnRH Receptor Antagonists Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 GnRH Receptor Antagonists Market Dynamics
  1. 2.1 GnRH Receptor Antagonists Industry Trends
  2. 2.2 GnRH Receptor Antagonists Industry Drivers
  3. 2.3 GnRH Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 GnRH Receptor Antagonists Industry Restraints
3 GnRH Receptor Antagonists Market by Company
  1. 3.1 Global GnRH Receptor Antagonists Company Revenue Ranking in 2025
  2. 3.2 Global GnRH Receptor Antagonists Revenue by Company (2021-2026)
  3. 3.3 Global GnRH Receptor Antagonists Sales Volume by Company (2021-2026)
  4. 3.4 Global GnRH Receptor Antagonists Average Price by Company (2021-2026)
  5. 3.5 Global GnRH Receptor Antagonists Company Ranking (2024-2026)
  6. 3.6 Global GnRH Receptor Antagonists Company Manufacturing Base and Headquarters
  7. 3.7 Global GnRH Receptor Antagonists Company Product Type and Application
  8. 3.8 Global GnRH Receptor Antagonists Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global GnRH Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 GnRH Receptor Antagonists Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 GnRH Receptor Antagonists Market by Type
  1. 4.1 GnRH Receptor Antagonists Type Introduction
  2. 4.1.1 Peptides
  3. 4.1.2 Small Molecules
  4. 4.2 Global GnRH Receptor Antagonists Sales Volume by Type
  5. 4.2.1 Global GnRH Receptor Antagonists Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GnRH Receptor Antagonists Sales Volume by Type (2021-2032)
  7. 4.2.3 Global GnRH Receptor Antagonists Sales Volume Share by Type (2021-2032)
  8. 4.3 Global GnRH Receptor Antagonists Sales Value by Type
  9. 4.3.1 Global GnRH Receptor Antagonists Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global GnRH Receptor Antagonists Sales Value by Type (2021-2032)
  11. 4.3.3 Global GnRH Receptor Antagonists Sales Value Share by Type (2021-2032)
5 GnRH Receptor Antagonists Market by Application
  1. 5.1 GnRH Receptor Antagonists Application Introduction
  2. 5.1.1 Endometriosis
  3. 5.1.2 Uterine Fibroids
  4. 5.1.3 Prostate Cancer
  5. 5.1.4 Female Infertility
  6. 5.1.5 Others
  7. 5.2 Global GnRH Receptor Antagonists Sales Volume by Application
  8. 5.2.1 Global GnRH Receptor Antagonists Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global GnRH Receptor Antagonists Sales Volume by Application (2021-2032)
  10. 5.2.3 Global GnRH Receptor Antagonists Sales Volume Share by Application (2021-2032)
  11. 5.3 Global GnRH Receptor Antagonists Sales Value by Application
  12. 5.3.1 Global GnRH Receptor Antagonists Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global GnRH Receptor Antagonists Sales Value by Application (2021-2032)
  14. 5.3.3 Global GnRH Receptor Antagonists Sales Value Share by Application (2021-2032)
6 GnRH Receptor Antagonists Regional Sales and Value Analysis
  1. 6.1 Global GnRH Receptor Antagonists Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GnRH Receptor Antagonists Sales by Region (2021-2032)
  3. 6.2.1 Global GnRH Receptor Antagonists Sales by Region: 2021-2026
  4. 6.2.2 Global GnRH Receptor Antagonists Sales by Region (2027-2032)
  5. 6.3 Global GnRH Receptor Antagonists Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global GnRH Receptor Antagonists Sales Value by Region (2021-2032)
  7. 6.4.1 Global GnRH Receptor Antagonists Sales Value by Region: 2021-2026
  8. 6.4.2 Global GnRH Receptor Antagonists Sales Value by Region (2027-2032)
  9. 6.5 Global GnRH Receptor Antagonists Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America GnRH Receptor Antagonists Sales Value (2021-2032)
  12. 6.6.2 North America GnRH Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe GnRH Receptor Antagonists Sales Value (2021-2032)
  15. 6.7.2 Europe GnRH Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific GnRH Receptor Antagonists Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific GnRH Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America GnRH Receptor Antagonists Sales Value (2021-2032)
  21. 6.9.2 South America GnRH Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa GnRH Receptor Antagonists Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa GnRH Receptor Antagonists Sales Value Share by Country, 2025 VS 2032
7 GnRH Receptor Antagonists Country-level Sales and Value Analysis
  1. 7.1 Global GnRH Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GnRH Receptor Antagonists Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global GnRH Receptor Antagonists Sales by Country (2021-2032)
  4. 7.3.1 Global GnRH Receptor Antagonists Sales by Country (2021-2026)
  5. 7.3.2 Global GnRH Receptor Antagonists Sales by Country (2027-2032)
  6. 7.4 Global GnRH Receptor Antagonists Sales Value by Country (2021-2032)
  7. 7.4.1 Global GnRH Receptor Antagonists Sales Value by Country (2021-2026)
  8. 7.4.2 Global GnRH Receptor Antagonists Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt GnRH Receptor Antagonists Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt GnRH Receptor Antagonists Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt GnRH Receptor Antagonists Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Ferring Pharmaceuticals
  2. 8.1.1 Ferring Pharmaceuticals Company Information
  3. 8.1.2 Ferring Pharmaceuticals Business Overview
  4. 8.1.3 Ferring Pharmaceuticals GnRH Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Ferring Pharmaceuticals GnRH Receptor Antagonists Product Portfolio
  6. 8.1.5 Ferring Pharmaceuticals Recent Developments
  7. 8.2 Kissei
  8. 8.2.1 Kissei Company Information
  9. 8.2.2 Kissei Business Overview
  10. 8.2.3 Kissei GnRH Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Kissei GnRH Receptor Antagonists Product Portfolio
  12. 8.2.5 Kissei Recent Developments
  13. 8.3 Myovant Sciences
  14. 8.3.1 Myovant Sciences Company Information
  15. 8.3.2 Myovant Sciences Business Overview
  16. 8.3.3 Myovant Sciences GnRH Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Myovant Sciences GnRH Receptor Antagonists Product Portfolio
  18. 8.3.5 Myovant Sciences Recent Developments
  19. 8.4 Veru Inc
  20. 8.4.1 Veru Inc Company Information
  21. 8.4.2 Veru Inc Business Overview
  22. 8.4.3 Veru Inc GnRH Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Veru Inc GnRH Receptor Antagonists Product Portfolio
  24. 8.4.5 Veru Inc Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca GnRH Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca GnRH Receptor Antagonists Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 AbbVie
  32. 8.6.1 AbbVie Company Information
  33. 8.6.2 AbbVie Business Overview
  34. 8.6.3 AbbVie GnRH Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AbbVie GnRH Receptor Antagonists Product Portfolio
  36. 8.6.5 AbbVie Recent Developments
  37. 8.7 Astellas
  38. 8.7.1 Astellas Company Information
  39. 8.7.2 Astellas Business Overview
  40. 8.7.3 Astellas GnRH Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Astellas GnRH Receptor Antagonists Product Portfolio
  42. 8.7.5 Astellas Recent Developments
  43. 8.8 Jiangsu Hengrui Medicine Co
  44. 8.8.1 Jiangsu Hengrui Medicine Co Company Information
  45. 8.8.2 Jiangsu Hengrui Medicine Co Business Overview
  46. 8.8.3 Jiangsu Hengrui Medicine Co GnRH Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Jiangsu Hengrui Medicine Co GnRH Receptor Antagonists Product Portfolio
  48. 8.8.5 Jiangsu Hengrui Medicine Co Recent Developments
  49. 8.9 Takeda
  50. 8.9.1 Takeda Company Information
  51. 8.9.2 Takeda Business Overview
  52. 8.9.3 Takeda GnRH Receptor Antagonists Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Takeda GnRH Receptor Antagonists Product Portfolio
  54. 8.9.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GnRH Receptor Antagonists Value Chain Analysis
  2. 9.1.1 GnRH Receptor Antagonists Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GnRH Receptor Antagonists Sales Mode & Process
  6. 9.2 GnRH Receptor Antagonists Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GnRH Receptor Antagonists Distributors
  9. 9.2.3 GnRH Receptor Antagonists Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst